This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.
Activity Details
469 * | Wed, 8/4/2010, 8:30 AM - 10:20 AM | CC-216 (West) |
Topics in Clinical Trials — Contributed Papers | ||
Biopharmaceutical Section | ||
Chair(s): Richard Caplan, AstraZeneca | ||
8:35 AM | The Case for Embedding a Detailed Statistical Analysis Plan in Clinical Trial Protocols — Chris Assaid, Merck Research Laboratories ; Keaven M. Anderson, Merck Research Laboratories | |
8:50 AM | The Benefit of Stratified Clinical Trials Revisited — Jitendra Ganju, Amgen Inc. ; Kefei Zhou, Amgen Inc. | |
9:05 AM | Application of Methods for Assessing Risk-Benefit in Clinical Trials — Menghui Chen, Merck & Co., Inc. ; Shailaja Suryawanshi, Merck & Co., Inc. | |
9:20 AM | Assessing Treatment Effect in Clinical Trials with Dichotomous Endpoints — Gang Jia, Merck & Co., Inc. | |
9:35 AM | A 'Paradox' in the Use of an ANCOVA Model in Determination of Treatment Effect in Clinical Trials — Chi-Hse Teng, Amylin Pharmaceuticals ; Larry Z. Shen, Amylin Pharmaceuticals ; Ping Yan, Amylin Pharmaceuticals | |
9:50 AM | Benefit Risk Assessment Incorporating Time Component — Paulette Ceesay, Merck & Co., Inc. ; Richard Entsuah, Merck & Co., Inc. | |
10:05 AM | Floor Discussion |
2010 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.